vs

Side-by-side financial comparison of Aligos Therapeutics, Inc. (ALGS) and Aris Mining Corp (ARMN). Click either name above to swap in a different company.

Aligos Therapeutics, Inc. is the larger business by last-quarter revenue ($169.0K vs $151.1K, roughly 1.1× Aris Mining Corp).

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.

Endeavour Mining plc is a multinational mining company that owns and operates gold mines in Côte d'Ivoire, Burkina Faso and Senegal. The company is headquartered in London, England, and is listed on the London Stock Exchange. It is a constituent of the FTSE 100 Index.

ALGS vs ARMN — Head-to-Head

Bigger by revenue
ALGS
ALGS
1.1× larger
ALGS
$169.0K
$151.1K
ARMN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ALGS
ALGS
ARMN
ARMN
Revenue
$169.0K
$151.1K
Net Profit
$20.5K
Gross Margin
44.9%
Operating Margin
30.0%
Net Margin
13.6%
Revenue YoY
-72.1%
Net Profit YoY
75.8%
EPS (diluted)
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALGS
ALGS
ARMN
ARMN
Q4 25
$169.0K
$151.1K
Q3 25
$741.0K
Q2 25
$965.0K
Q1 25
$311.0K
Q4 24
$606.0K
Q3 24
$1.3M
Q2 24
$1.1M
Q1 24
$694.0K
Net Profit
ALGS
ALGS
ARMN
ARMN
Q4 25
$20.5K
Q3 25
$-31.5M
Q2 25
$-15.9M
Q1 25
$43.1M
Q4 24
$-82.2M
Q3 24
$-19.3M
Q2 24
$5.1M
Q1 24
$-34.9M
Gross Margin
ALGS
ALGS
ARMN
ARMN
Q4 25
44.9%
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
ALGS
ALGS
ARMN
ARMN
Q4 25
30.0%
Q3 25
-3827.4%
Q2 25
-1924.0%
Q1 25
-6187.5%
Q4 24
-3393.2%
Q3 24
-1610.5%
Q2 24
-2489.5%
Q1 24
-3176.7%
Net Margin
ALGS
ALGS
ARMN
ARMN
Q4 25
13.6%
Q3 25
-4256.0%
Q2 25
-1643.8%
Q1 25
13854.7%
Q4 24
-13556.1%
Q3 24
-1540.7%
Q2 24
477.0%
Q1 24
-5023.5%
EPS (diluted)
ALGS
ALGS
ARMN
ARMN
Q4 25
$0.02
Q3 25
$-3.04
Q2 25
$-1.53
Q1 25
$-2.11
Q4 24
$-13.10
Q3 24
$-3.07
Q2 24
$0.81
Q1 24
$-5.58

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALGS
ALGS
ARMN
ARMN
Cash + ST InvestmentsLiquidity on hand
$77.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$53.5M
Total Assets
$88.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALGS
ALGS
ARMN
ARMN
Q4 25
$77.8M
Q3 25
$99.1M
Q2 25
$122.9M
Q1 25
$137.9M
Q4 24
$56.9M
Q3 24
$74.9M
Q2 24
$94.5M
Q1 24
$112.7M
Stockholders' Equity
ALGS
ALGS
ARMN
ARMN
Q4 25
$53.5M
Q3 25
$71.8M
Q2 25
$101.9M
Q1 25
$116.4M
Q4 24
$-29.0M
Q3 24
$50.1M
Q2 24
$67.2M
Q1 24
$59.8M
Total Assets
ALGS
ALGS
ARMN
ARMN
Q4 25
$88.5M
Q3 25
$109.8M
Q2 25
$134.7M
Q1 25
$150.7M
Q4 24
$70.1M
Q3 24
$88.4M
Q2 24
$108.8M
Q1 24
$127.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALGS
ALGS
ARMN
ARMN
Operating Cash FlowLast quarter
$-82.5M
$99.1K
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
4.82×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALGS
ALGS
ARMN
ARMN
Q4 25
$-82.5M
$99.1K
Q3 25
$-24.3M
Q2 25
$-15.5M
Q1 25
$-20.9M
Q4 24
$-18.4M
Q3 24
$-20.1M
Q2 24
$-19.5M
Q1 24
$-22.7M
Cash Conversion
ALGS
ALGS
ARMN
ARMN
Q4 25
4.82×
Q3 25
Q2 25
Q1 25
-0.49×
Q4 24
Q3 24
Q2 24
-3.85×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons